134517-34-3

Basic information

• Product Name: 2-[(2-CHLOROQUINAZOLIN-4-YL)AMINO]ETHANOL
• Synonyms: Ethanol, 2-[(2-chloro-4-quinazolinyl)amino]-
• CAS NO: 134517-34-3
• Molecular Formula: C₁₀H₁₀ClN₃O
• Molecular Weight: 223.66
• Mol File: 134517-34-3.mol

Chemical Properties

• Boiling Point: 334.5°Cat760mmHg
• Flash Point: 156.1°C
• Appearance: /
• Density: 1.439g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.713
• CAS DataBase Reference: 2-[(2-CHLOROQUINAZOLIN-4-YL)AMINO]ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2-CHLOROQUINAZOLIN-4-YL)AMINO]ETHANOL(134517-34-3)
• EPA Substance Registry System: 2-[(2-CHLOROQUINAZOLIN-4-YL)AMINO]ETHANOL(134517-34-3)

Safety Data

• Hazardous Substances Data: 134517-34-3(Hazardous Substances Data)

Usage

Type of compound

Chemical compound

Usage

Commonly used in the synthesis of pharmaceutical drugs and organic compounds

Applications

Building block for the synthesis of potential anti-cancer and anti-inflammatory drugs, valuable intermediate in the production of various pharmacologically active substances

Additional uses

Reagent in organic chemistry to create a variety of complex molecules.

InChI:InChI=1/C10H10ClN3O/c11-10-13-8-4-2-1-3-7(8)9(14-10)12-5-6-15/h1-4,15H,5-6H2,(H,12,13,14)

Upstream product

• 607-68-1 2,4-dichloroquinazoline 
• 141-43-5 ethanolamine 

Relevant articles and documents

QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER

The present disclosure relates generally to a class of quinazoline compounds, compositions containing the same and the therapeutic use of the compounds in the treatment of cancer.

Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity

Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.

Heterocyclic compounds and their preparation and use

New imidazoquinazoline compounds having the general formula STR1 wherein A together with the α-marked carbon atom and the β-marked nitrogen atom is one of the groups STR2 wherein R4, R5, R6 and R7 independently are hydrogen, halogen C1-6 -alkyl, aryl or aralkyl R1 is STR3 cyano or CO2 R8, wherein R8 is hydrogen, C1-6 -alkyl or C3-7 -cycloalkyl, trifluoromethyl or C1-6 -alkoxymethyl, R2 and R3 independently are hydrogen, halogen, CN, C1-6 -alkyl, C2-6 -alkenyl, C2-6 -alkynyl, trifluoromethyl, C1-6 -alkoxy, dialkylaminoalkoxy, aralkoxy, aryloxy which may be substituted with halogen or alkoxy, a cyclic amino group, or NR9 R10, wherein R9 and R10 independently are hydrogen or C1-6 -alkyl. The compounds are useful in psychopharmaceutical preparations as anticonvusants, anxiolytics, hypnotics, antipsychotics, antiemetics, or in improving the cognitive function of the brain of mammals.